Merck Shares Rise Slightly After $6.7 Billion Terns Deal Strengthens Cancer Pipeline Prospects

TLDRs;

• Merck stock climbs after revealing $6.7B deal to acquire Terns
• Oncology expansion strategy is driven by impending Keytruda patent loss
• Leukemia treatment TERN-701 emerges as key pipeline asset
• Investors balance small premium with prospects for long-term pipeline expansion

(SeaPRwire) –   Shares of Merck & Co. (NYSE: MRK) moved slightly higher after the firm disclosed a $6.7 billion all-cash purchase of Terns Pharmaceuticals (NASDAQ: TERN). Valued at $53 per share, the agreement marks a fresh effort by the drugmaker to bolster its cancer drug pipeline ahead of the approaching patent expiry for its top-selling therapy, Keytruda.

The market’s reaction showed guarded optimism, as investors see the purchase as a tactical play to lock in future income sources against rising competition in cancer therapeutics.

Keytruda Pressure Drives Strategy

This acquisition occurs at a pivotal moment for Merck, with its leading immunotherapy, Keytruda, anticipating patent cliffs starting in 2028. In 2025, Keytruda produced more than $30 billion in sales, making up almost half of Merck’s total revenue.

Merck & Co., Inc., MRK

Given this significant dependence on one product, Merck has hastened initiatives to broaden its oncology offerings. The Terns transaction is a deliberate move in this plan, intended to lessen long-term reliance on Keytruda and fortify the company’s standing in new cancer treatment fields.

TERN-701 Becomes Core Asset

The focal point of the deal is TERN-701, an investigational oral treatment for chronic myeloid leukemia, a cancer of the blood and bone marrow. Initial clinical results have been positive, showing a response rate of approximately 75% in patients who had prior treatment.

Merck’s research leaders have called the drug’s early data promising, indicating it may provide a distinct method in a competitive area of blood cancer care. Should it succeed in advanced trials, TERN-701 could position Merck to compete directly with existing market-leading therapies.

Market Reaction and Valuation Debate

Although a large transaction, the upfront premium for Terns shareholders seemed fairly small, with the offer price reflecting only a slight percentage gain over recent trading prices. Nonetheless, Terns stock surged in premarket activity as the acquisition certainty prompted investor response.

Analysts commented that while the price tag may be debatable, the strategic importance of the pipeline asset is greater than near-term cost worries. Some watchers, however, proposed the low premium might draw attention from other potential buyers, though no rival bids have surfaced yet.

Broader Acquisition Strategy Expands

The Terns agreement is the most recent in a string of purchases by Merck focused on enhancing its long-term growth potential. In the last year, the company has finalized several deals in biotechnology and specialty pharmaceuticals, all meant to develop capabilities beyond Keytruda.

These actions are components of a wider reorganization within Merck’s human health segment, which recently divided its business into units focused on oncology and non-oncology areas. This change underscores the ongoing importance of cancer drugs in the corporate strategy, even as it investigates other treatment domains.

Outlook

While the deal still needs regulatory clearance and shareholder support, market mood points to increasing belief in Merck’s long-term cancer strategy.

Investors are now monitoring closely to determine if TERN-701 can advance effectively through clinical testing and validate its potential as a future mainstay of Merck’s oncology portfolio.